Bio-Thera Initiates P-I Study of BAT2206 Proposed Biosimilar to Stelara (ustekinumab)

 Bio-Thera Initiates P-I Study of BAT2206 Proposed Biosimilar to Stelara (ustekinumab)

Shots:

  • The first patient has been dosed in a P-I clinical study to compare the PK and safety of BAT2206, a proposed biosimilar to Stelara (ustekinumab) to US/EU-sourced reference product in healthy volunteers
  • The company is expected to enroll 270 healthy volunteers. BAT2206 represents the fifth biosimilar of Bio-Thera’s portfolio that has advanced into clinical development
  • BioThera is developing additional products, including QLETLI (biosimilar to Humira), which is approved in China, BAT1706 (biosimilar to Avastin), that has completed a P-III study with expected regulatory submission in Q4’20. The company is also pursuing biosimilar versions of Actemra, Cosentyx, and Simponi

Click here ­to­ read full press release/ article | Ref: BioThera | Image: Long Term Care Rx

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post